We conducted a randomized, double-blind trial of 383 patients who had a first acute clinical demyelinating event (optic neuritis, incomplete transverse myelitis, or a brain-stem or cerebellar ...

Argenx has a second FDA approval for FcRn inhibitor Vyvgart Hytrulo, adding new indication rare autoimmune disease CIDP.

Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).